181 related articles for article (PubMed ID: 7584882)
21. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa.
Muñoz MT; Morandé G; García-Centenera JA; Hervás F; Pozo J; Argente J
Eur J Endocrinol; 2002 Jan; 146(1):45-50. PubMed ID: 11751066
[TBL] [Abstract][Full Text] [Related]
22. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
Dunzendorfer U; Schulz H
Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845
[TBL] [Abstract][Full Text] [Related]
23. Plasma androgen levels after subcapsular orchiectomy or estrogen treatment for prostatic carcinoma.
Vermeulen A; Schelfhout W; De Sy W
Prostate; 1982; 3(2):115-21. PubMed ID: 6211662
[TBL] [Abstract][Full Text] [Related]
24. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
Lundgren R; Nordle O; Josefsson K
J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
[TBL] [Abstract][Full Text] [Related]
25. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
Lindstedt E
Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
[TBL] [Abstract][Full Text] [Related]
26. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.
Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O
Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233
[TBL] [Abstract][Full Text] [Related]
27. Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogens.
Stege R; Carlström K; Eriksson A; Gustafsson SA; Henriksson P; Pousette A
Urol Int; 1987; 42(2):124-6. PubMed ID: 3617239
[TBL] [Abstract][Full Text] [Related]
28. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Hedlund PO; Henriksson P
Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
[TBL] [Abstract][Full Text] [Related]
29. Treatment of prostatic cancer: effects on serum lipoproteins and the cardiovascular system.
Rössner S; Hedlund PO; Jogestrand T; Säwe U
J Urol; 1985 Jan; 133(1):53-7. PubMed ID: 3964880
[TBL] [Abstract][Full Text] [Related]
30. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group.
Haapiainen R; Rannikko S; Alfthan O
Br J Urol; 1990 Jul; 66(1):94-7. PubMed ID: 2132303
[TBL] [Abstract][Full Text] [Related]
31. Estrogen therapy for prostate carcinoma.
Presti JC
JAMA; 1996 Apr; 275(15):1153. PubMed ID: 8609673
[No Abstract] [Full Text] [Related]
32. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
Johansson JE; Andersson SO; Holmberg L; Bergström R
J Urol; 1991 Mar; 145(3):519-22; discussion 522-3. PubMed ID: 1997702
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol ester metabolism in plasma during estrogen and antiandrogen treatment in men with carcinoma of the prostate.
Wallentin L; Varenhorst E
J Lab Clin Med; 1981 Dec; 98(6):906-16. PubMed ID: 6458644
[TBL] [Abstract][Full Text] [Related]
34. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.
Damber JE; Daehlin L; Tomic R; Nilsson TK
Int Urol Nephrol; 1991; 23(3):251-6. PubMed ID: 1889971
[TBL] [Abstract][Full Text] [Related]
35. Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
Aro J; Haapiainen R; Sane T; Rannikko S; Pelkonen R; Alfthan O
Eur Urol; 1990; 17(3):229-35. PubMed ID: 2351192
[TBL] [Abstract][Full Text] [Related]
36. [Surgical and hormonal therapy of prostatic carcinoma].
Frick J
Wien Med Wochenschr; 1977 Aug; 127(15):480-2. PubMed ID: 906541
[No Abstract] [Full Text] [Related]
37. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients.
Aro J; Haapiainen R; Rasi V; Rannikko S; Alfthan O
Eur Urol; 1990; 17(2):161-5. PubMed ID: 2178941
[TBL] [Abstract][Full Text] [Related]
38. Tissue PSA is the best predicting variable for the outcome of endocrine treatment of prostatic carcinoma.
Pousette A; Grande M; Carlström K; Stege R
Scand J Clin Lab Invest Suppl; 1999; 229():27-32. PubMed ID: 10097287
[TBL] [Abstract][Full Text] [Related]
39. re: Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. R. Haapiainen et al. Br. J. Urol., 66, 94-97, 1990.
Bishop MC
Br J Urol; 1991 Aug; 68(2):218. PubMed ID: 1884161
[No Abstract] [Full Text] [Related]
40. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
